When Will Retatrutide Be Available? FDA Approval Timeline
When will retatrutide be available? Retatrutide remains investigational. Lilly's 29 September 2026 release says it cannot legally be sold or marketed for human use, and outside its trials the only route listed on ClinicalTrials.gov is a narrow pre-approval expanded access programme. The short version: Lilly said in July 2026 that it plans to file a Biologics License Application in the first quarter of 2027.2 The FDA's drug review page, which is written about New Drug Applications, gives a general window of 6 to 10 months to decide once a complete application is filed.4 Used as plain arithmetic, those two public facts place a first decision no earlier than mid to late 2027, if filed on time and accepted. This is not a company forecast.
Sources: ClinicalTrials.gov, Lilly pre-approval expanded access, NCT07629401; Eli Lilly, TRIUMPH-2 results, investigational status and planned Q1 2027 BLA, 29 September 2026
Quick answer
- Is retatrutide available now?
- Not as an approved medicine. Retatrutide is investigational; outside Lilly's trials, the only legal route listed on ClinicalTrials.gov is a narrow Lilly pre-approval expanded access programme for adults with severe obesity and serious complications who cannot join a trial.
- When could it be approved?
- Lilly plans to file with the FDA in Q1 2027.2 The FDA's general 6 to 10 month review window, published on its New Drug Application review page,4 would place a first decision no earlier than mid to late 2027, if filed on time and accepted. That is arithmetic, not a forecast from Lilly.
Sources: ClinicalTrials.gov, Lilly pre-approval expanded access, NCT07629401
Investigational
Lilly statement, 29 Sep 2026
Q1 2027
When Lilly plans to file with the FDA2
6 to 10 mo
General FDA review window (NDA page)4
Sources: Eli Lilly, TRIUMPH-2 results, investigational status and planned Q1 2027 BLA, 29 September 2026
Where Retatrutide Stands Today
Lilly describes retatrutide as an investigational triple hormone receptor agonist. Its latest release, dated 29 September 2026, says retatrutide cannot legally be sold or marketed for human use. Its main phase 3 obesity trials have finished enrolling and several have completed,1 but completing a trial is not the same as approval: Lilly plans a US submission, and the FDA review process described below comes before an approval decision. For the compound itself and its trial history, see the retatrutide profile.
Lilly describes retatrutide as investigational, and its 29 September 2026 release says it cannot legally be sold or marketed for human use. ClinicalTrials.gov lists a narrow pre-approval expanded access programme as the only route outside its trials. Material sold outside those routes is not an approved medicine, and this page does not verify or classify individual products.
Sources: ClinicalTrials.gov, Lilly pre-approval expanded access, NCT07629401; Eli Lilly, TRIUMPH-2 results, investigational status and planned Q1 2027 BLA, 29 September 2026
What Eli Lilly Has Said About Timing
The clearest public statement on timing comes from Lilly itself. In a news release dated July 23, 2026, the company said it is completing the manufacturing data package, the Chemistry, Manufacturing, and Controls package, required for a Biologics License Application, and plans to submit retatrutide to the FDA in the first quarter of 2027 for US approval.2 That is a plan to file, not an approval date.
In its July 23, 2026 release, Lilly published no predicted approval date.2 A plan to file in Q1 2027 tells you when the application is expected to reach the FDA, not when, or whether, the agency will clear it.
What Has to Happen Before Approval
Filing an application starts a process with its own clock. In its description of the drug review step, the FDA says that once it receives a New Drug Application, the review team first decides whether it is complete, and it can refuse to file one that is not.4 If the application is complete, the review team has 6 to 10 months to decide whether to approve the drug.4 That page describes New Drug Application review, while Lilly plans a Biologics License Application,2 so this page uses the 6 to 10 month figure only as the general window the FDA publishes, for arithmetic. Nothing in the sources reviewed here is a retatrutide-specific FDA timetable, and whether this filing would draw a standard or a faster review is not established here.
The arithmetic, spelled out
A Q1 2027 submission2 plus the FDA's general 6 to 10 month review window4 places a first decision no earlier than mid to late 2027, if filed on time and accepted. This is arithmetic from two public facts, Lilly's stated filing quarter and the general review range on the FDA's New Drug Application review page, applied here to a planned Biologics License Application. It is not a prediction from Lilly, and it is not a promise that approval will happen at all.
The Phase 3 TRIUMPH Trials
ClinicalTrials.gov lists a programme of phase 3 TRIUMPH studies for retatrutide. Below are those trials with the primary completion dates registered on ClinicalTrials.gov, read on 30 September 2026.1 TRIUMPH-1, TRIUMPH-2, and TRIUMPH-3 are all listed as completed.
| Trial | Population | Registry ID | Status | Primary completion |
|---|---|---|---|---|
| TRIUMPH-1 | Obesity or overweight | NCT05929066 | Completed | 2026-04-06 |
| TRIUMPH-2 | Type 2 diabetes with obesity or overweight | NCT05929079 | Completed | 2026-06-16 |
| TRIUMPH-3 | BMI 35 or higher with established cardiovascular disease | NCT05882045 | Completed | 2026-04-16 |
| TRIUMPH-4 | Obesity and knee osteoarthritis | NCT05931367 | Completed | 2025-11-14 |
| TRIUMPH-5 | Head to head vs tirzepatide | NCT06662383 | Active, not recruiting | 2026-11 |
| TRIUMPH-6 | Maintenance of weight reduction | NCT06859268 | Active, not recruiting | 2028-04 |
| TRIUMPH-7 | Obesity and chronic low back pain | NCT07035093 | Active, not recruiting | 2027-09 |
| TRIUMPH-8 | Obesity or overweight | NCT07232719 | Active, not recruiting | 2027-07 |
| TRIUMPH-9 | Obesity or overweight without type 2 diabetes | NCT07357415 | Active, not recruiting | 2028-10 |
| TRIUMPH-Outcomes | Cardiovascular and kidney outcomes | NCT06383390 | Active, not recruiting | 2029-02 |
Related diabetes trials, TRANSCEND-T2D-1, TRANSCEND-T2D-2, and TRANSCEND-T2D-3, and a metabolic liver-disease study, SYNERGY-Outcomes, sit alongside the TRIUMPH set on the registry. SYNERGY-Outcomes is the only phase 3 retatrutide study still showing a recruiting status; every TRIUMPH trial is either completed or active and no longer recruiting.1
What the Trials Have Shown
This page is about timing, not dosing, so the results here are context, not instructions. In TRIUMPH-1, the pivotal obesity trial, the published New England Journal of Medicine paper reported, for the treatment-regimen estimand (intention-to-treat, ITT), a mean percent change in body weight of -25.0% at 12 mg (trial dose, not a recommendation, PMID 42814954) versus -3.9% with placebo over 80 weeks.5 Lilly's earlier May 2026 press release reported a higher topline figure for the same top-dose group;3 this page uses the peer-reviewed figure.
Two other completed trials report weight loss: TRIUMPH-2 in a peer-reviewed paper and TRIUMPH-3 in a company release. TRIUMPH-2, in adults with obesity and type 2 diabetes, has been published as a peer-reviewed paper in The Lancet, which reported, for the treatment-regimen estimand, a mean percentage change from baseline in body weight at week 80 of -11.9% at 4 mg (trial dose, not a recommendation, PMID 42810372), -16.8% at 9 mg (trial dose, not a recommendation, PMID 42810372), and -18.8% at 12 mg (trial dose, not a recommendation, PMID 42810372) versus -5.1% with placebo.6 Lilly's July 2026 release had reported a higher company topline for the same trial;2 as with TRIUMPH-1, this page leads with the peer-reviewed figures. TRIUMPH-3, in 1,949 adults with a BMI of 35 or higher and established cardiovascular disease, exists on this page only as company topline: for the efficacy estimand, Lilly's July 2026 release reported mean weight changes of -21.6% at 9 mg and -22.6% at 12 mg, against -3.2% on placebo at 80 weeks (trial doses, not a recommendation). A peer-reviewed TRIUMPH-3 paper was not found in our PubMed search, which may mean it is not yet published or not yet indexed, so treat those figures as unreviewed company results. An earlier phase 2 trial of retatrutide in obesity was published in the New England Journal of Medicine in 2023 (PMID 37366315).7
For the trial doses themselves, see the retatrutide dosage guide; for how retatrutide compares with tirzepatide, see retatrutide vs tirzepatide.
Sources: Eli Lilly, TRIUMPH-2 and TRIUMPH-3 results, 23 July 2026
Disclaimer: this is general education, not medical advice and not a dosing recommendation.
What Being Available Means Today
Lilly's 29 September 2026 release says retatrutide cannot legally be sold or marketed for human use. Outside its trials, ClinicalTrials.gov lists a Lilly pre-approval expanded access programme for adults with a BMI of 35 or more and at least two serious obesity-related complications who cannot join a trial. Among the phase 3 retatrutide studies, only SYNERGY-Outcomes, a trial in metabolic liver disease, still shows a recruiting status on ClinicalTrials.gov; the rest have stopped enrolling.1 That trial access is not pharmacy availability.
Lilly's 29 September 2026 statement above describes retatrutide as investigational. On that basis, research-grade material sold elsewhere is not an approved medicine.
For retatrutide, this page links to our supply partner, Peptara Labs. None of this changes the status above: research-grade material is not an approved medicine, and no lab document makes it one. For how a certificate of analysis is read line by line, see the COA verification guide.
Disclosure: Some links on this page are referral links. Peptides Vietnam may earn a fee at no cost to you. Editorial content is never sold.
This page does not cover dosing or country by country access. The retatrutide in Vietnam guide covers access here, the GLP-1 peptides in Vietnam guide compares it with the approved options, and the retatrutide calculator is for illustrative math, not a prediction of individual weight loss.
Sources: ClinicalTrials.gov, Lilly pre-approval expanded access, NCT07629401; Eli Lilly, TRIUMPH-2 results, investigational status and planned Q1 2027 BLA, 29 September 2026
What This Page Does Not Claim
A specific approval date
Lilly has stated a filing quarter, not an approval date. The mid to late 2027 earliest bound on this page is arithmetic from public facts, not a forecast.
Anything about regulators outside the United States
Lilly said in July 2026 that its clinical data package now supports global submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea, and its August 2026 earnings release said the same. Neither gives a filing date for Europe, Vietnam or any other market outside the US, so those dates remain unverified here.
Whether retatrutide will receive priority review
The 6 to 10 month window is the general range on the FDA drug review page, which is written about New Drug Applications and is used here as arithmetic for a planned Biologics License Application. Whether this specific application is granted a faster track is not something the sources establish.
That research-grade retatrutide equals an approved medicine
It does not. No version of retatrutide has passed the FDA review described above.
Sources: Eli Lilly, TRIUMPH-2 and TRIUMPH-3 results, 23 July 2026; Eli Lilly, Q2 2026 earnings release, 5 August 2026
Common Questions
When will retatrutide be available?+
Retatrutide remains investigational. Lilly's 29 September 2026 release says retatrutide cannot legally be sold or marketed for human use. Eli Lilly said in July 2026 that it plans to submit a Biologics License Application to the US Food and Drug Administration in the first quarter of 2027. The FDA drug review page, written about New Drug Applications, says the agency first decides whether an application is complete and, if it is, has 6 to 10 months to reach a decision. Using that general window as arithmetic places a first FDA decision no earlier than mid to late 2027, if filed on time and accepted. This is not a company forecast.
Is retatrutide FDA approved?+
No. Retatrutide is an investigational molecule with no approved label and no approved dose. Lilly's 29 September 2026 release says it cannot legally be sold or marketed for human use, and that Lilly plans to submit a Biologics License Application to the FDA in Q1 2027.
Has Eli Lilly said when it will file for approval?+
Yes. In a news release dated July 23, 2026, Lilly said it is completing the Chemistry, Manufacturing, and Controls data package required for a Biologics License Application and plans to submit retatrutide to the FDA in the first quarter of 2027 for US approval. That release did not give a predicted approval date.
How long does FDA review take after a submission?+
According to the FDA drug review page, once the agency receives a New Drug Application the review team first decides whether it is complete and can refuse to file one that is not. If the application is complete, the review team has 6 to 10 months to decide whether to approve the drug. Lilly plans a Biologics License Application, so this page treats that window as the general range the FDA publishes, not a retatrutide-specific timetable. The window starts only after a submission is filed and found complete.
Can I get retatrutide right now?+
Not as an approved medicine. Lilly's 29 September 2026 release describes retatrutide as investigational and says it cannot legally be sold or marketed for human use. Outside clinical trials, the only supervised route listed on ClinicalTrials.gov is a Lilly pre-approval expanded access programme (NCT07629401, first posted June 2026, status Available), limited to adults with a BMI of 35 or more and at least two serious obesity-related complications who have not responded to approved therapy and cannot join a trial. Every TRIUMPH trial is now completed or active and no longer recruiting. Research-grade material sold elsewhere is not an approved medicine.
What weight change did the retatrutide trials report?+
In TRIUMPH-1, the published New England Journal of Medicine paper reported, for the treatment-regimen estimand (intention-to-treat, ITT), a mean percent change in body weight of -25.0% at 12 mg (trial dose, not a recommendation, PMID 42814954) versus -3.9% with placebo over 80 weeks. That is a monitored trial result, not a promise for anyone else, and this page does not tell you what to take.
Sources: Eli Lilly, TRIUMPH-2 results, investigational status and planned Q1 2027 BLA, 29 September 2026; ClinicalTrials.gov, Lilly pre-approval expanded access, NCT07629401; ClinicalTrials.gov, retatrutide trial records
Disclaimer: this is general education, not medical advice and not a dosing recommendation.
Related reading
Retatrutide Dosage
What the phase 2 and phase 3 trials actually used
Retatrutide in Vietnam
What access looks like here, and how to vet a supplier
Retatrutide vs Tirzepatide
How retatrutide compares with tirzepatide
Retatrutide: Full Profile
Mechanism, trial history, and reported effects
GLP-1 Peptides in Vietnam
Semaglutide, tirzepatide, and retatrutide access in one place
Retatrutide Calculator
Illustrative math, not a prediction of individual weight loss
This guide is for educational purposes only and is not medical advice. It describes what public regulatory statements and published clinical trials report about retatrutide; it is not an endorsement, a recommendation, or an instruction to use any compound. Retatrutide is an investigational drug that is not approved for use. Consult a qualified healthcare professional before making any decision about your health.